Celgene and Evotec have put capital into Exscientia as the Dundee-founded automated drug discovery services provider added Roche to its roster of development partners.

Exscientia, a UK-based drug discovery technology spinout of University of Dundee, received $26m yesterday in a series B round backed by pharmaceutical developer Celgene and drug developer Evotec.
The deal also includes funding from venture firm GT Healthcare Capital Partners. Commercialisation firm Frontier IP, an existing investor in Exscientia, owns a 3.3% stake in the spinout following the transaction.
Founded in 2012, Exscientia has devised an automated drug discovery technology that applies artificial intelligence (AI) to understandings gained…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?